Skip to content
10-Q

Quarterly Report

Adamas Pharmaceuticals, Inc.

0001328143-20-000042

← back to feed
Filed
Aug 6, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2020 · Jul 31, 2020 28.28M sh
Long Term Debt Q2 2020 · Jun 30, 2020 $126.3M
Long Term Debt Q2 2020 · Dec 31, 2019 $125.67M
Short Term Debt Q2 2020 · Jun 30, 2020 $3.23M
Short Term Debt Q2 2020 · Dec 31, 2019 $2.04M
Short Term Investments Q2 2020 · Jun 30, 2020 $72.88M
Short Term Investments Q2 2020 · Dec 31, 2019 $66.83M
Cash And Equivalents Q2 2020 · Jun 30, 2020 $30.54M
Cash And Equivalents Q2 2020 · Dec 31, 2019 $65.77M
Current Liabilities Q2 2020 · Jun 30, 2020 $21.22M
Current Liabilities Q2 2020 · Dec 31, 2019 $26.95M
Total Liabilities Q2 2020 · Jun 30, 2020 $157.47M
Total Liabilities Q2 2020 · Dec 31, 2019 $163.05M
Current Assets Q2 2020 · Jun 30, 2020 $123.69M
Current Assets Q2 2020 · Dec 31, 2019 $150.32M
Total Assets Q2 2020 · Jun 30, 2020 $133.07M
Total Assets Q2 2020 · Dec 31, 2019 $162.16M
Capex Q2 2020 · Jun 30, 2019 $18K
Operating Cash Flow Q2 2020 · Jun 30, 2019 −$43.81M
Stockholders Equity Q2 2020 · Jun 30, 2019 $42.7M
Stockholders Equity Q2 2020 · Mar 31, 2019 $63.92M
Stockholders Equity Q2 2020 · Dec 31, 2018 $89.89M
Sga Expense Q2 2020 · Jun 30, 2019 $25.22M
Sga Expense Q2 2020 · Jun 30, 2019 $52.9M
Rd Expense Q2 2020 · Jun 30, 2019 $8.6M
Rd Expense Q2 2020 · Jun 30, 2019 $18.81M
Net Income Q2 2020 · Jun 30, 2019 −$24.87M
Net Income Q2 2020 · Jun 30, 2019 −$54.53M
Net Income Q2 2020 · Mar 31, 2019 −$29.66M
Operating Income Q2 2020 · Jun 30, 2019 −$21.81M
Operating Income Q2 2020 · Jun 30, 2019 −$48.46M
Cost Of Revenue Q2 2020 · Jun 30, 2019 $685K
Cost Of Revenue Q2 2020 · Jun 30, 2019 $1.1M
Revenue Q2 2020 · Jun 30, 2019 $12.69M
Revenue Q2 2020 · Jun 30, 2019 $24.36M